JP2016520622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520622A5 JP2016520622A5 JP2016517073A JP2016517073A JP2016520622A5 JP 2016520622 A5 JP2016520622 A5 JP 2016520622A5 JP 2016517073 A JP2016517073 A JP 2016517073A JP 2016517073 A JP2016517073 A JP 2016517073A JP 2016520622 A5 JP2016520622 A5 JP 2016520622A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- group
- hexitol derivative
- treatment
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical class OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 claims 156
- 239000003814 drug Substances 0.000 claims 85
- 238000011282 treatment Methods 0.000 claims 83
- 201000011510 cancer Diseases 0.000 claims 76
- 208000003174 Brain Neoplasms Diseases 0.000 claims 70
- 206010018338 Glioma Diseases 0.000 claims 66
- 230000000694 effects Effects 0.000 claims 66
- 230000000306 recurrent effect Effects 0.000 claims 66
- 239000003112 inhibitor Substances 0.000 claims 57
- 230000000750 progressive effect Effects 0.000 claims 54
- 208000032612 Glial tumor Diseases 0.000 claims 46
- 238000000034 method Methods 0.000 claims 44
- 239000003795 chemical substances by application Substances 0.000 claims 43
- 230000001965 increasing effect Effects 0.000 claims 43
- 229940079593 drug Drugs 0.000 claims 35
- 229940002612 prodrug Drugs 0.000 claims 33
- 239000000651 prodrug Substances 0.000 claims 33
- 230000006872 improvement Effects 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 229940124597 therapeutic agent Drugs 0.000 claims 15
- 238000002651 drug therapy Methods 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 12
- 230000014509 gene expression Effects 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 12
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 11
- 238000002360 preparation method Methods 0.000 claims 11
- 230000001225 therapeutic effect Effects 0.000 claims 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 235000018102 proteins Nutrition 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- AAFJXZWCNVJTMK-GUCUJZIJSA-N (1s,2r)-1-[(2s)-oxiran-2-yl]-2-[(2r)-oxiran-2-yl]ethane-1,2-diol Chemical compound C([C@@H]1[C@H](O)[C@H](O)[C@H]2OC2)O1 AAFJXZWCNVJTMK-GUCUJZIJSA-N 0.000 claims 9
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 9
- 230000001186 cumulative effect Effects 0.000 claims 9
- 229940043355 kinase inhibitor Drugs 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims 8
- 108090001008 Avidin Proteins 0.000 claims 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 8
- 238000012377 drug delivery Methods 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 8
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 8
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 7
- 102000001253 Protein Kinase Human genes 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 7
- 208000005017 glioblastoma Diseases 0.000 claims 7
- 238000007726 management method Methods 0.000 claims 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 108060006633 protein kinase Proteins 0.000 claims 7
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 7
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 7
- 102000004190 Enzymes Human genes 0.000 claims 6
- 108090000790 Enzymes Proteins 0.000 claims 6
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 6
- 108010090804 Streptavidin Proteins 0.000 claims 6
- 102000004338 Transferrin Human genes 0.000 claims 6
- 108090000901 Transferrin Proteins 0.000 claims 6
- 229960002685 biotin Drugs 0.000 claims 6
- 239000011616 biotin Substances 0.000 claims 6
- 229960001948 caffeine Drugs 0.000 claims 6
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 6
- 229950000758 dianhydrogalactitol Drugs 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 238000001802 infusion Methods 0.000 claims 6
- 230000036457 multidrug resistance Effects 0.000 claims 6
- 230000019491 signal transduction Effects 0.000 claims 6
- 239000012730 sustained-release form Substances 0.000 claims 6
- 230000008685 targeting Effects 0.000 claims 6
- 239000012581 transferrin Substances 0.000 claims 6
- 206010065553 Bone marrow failure Diseases 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims 5
- 229940093265 berberine Drugs 0.000 claims 5
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims 5
- 230000027455 binding Effects 0.000 claims 5
- 239000011230 binding agent Substances 0.000 claims 5
- 230000008499 blood brain barrier function Effects 0.000 claims 5
- 210000001218 blood-brain barrier Anatomy 0.000 claims 5
- 108091006116 chimeric peptides Proteins 0.000 claims 5
- 229960001338 colchicine Drugs 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003623 enhancer Substances 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 238000013268 sustained release Methods 0.000 claims 5
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims 4
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims 4
- 108010088751 Albumins Proteins 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 102000003964 Histone deacetylase Human genes 0.000 claims 4
- 108090000353 Histone deacetylase Proteins 0.000 claims 4
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 claims 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 4
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims 4
- 206010070834 Sensitisation Diseases 0.000 claims 4
- 229940122149 Thymidylate synthase inhibitor Drugs 0.000 claims 4
- 229940122803 Vinca alkaloid Drugs 0.000 claims 4
- MMAXAFOTGLVFQZ-UHFFFAOYSA-N [2-acetyloxy-1,2-bis(oxiran-2-yl)ethyl] acetate Chemical compound C1OC1C(OC(=O)C)C(OC(C)=O)C1CO1 MMAXAFOTGLVFQZ-UHFFFAOYSA-N 0.000 claims 4
- 229940100198 alkylating agent Drugs 0.000 claims 4
- 239000002168 alkylating agent Substances 0.000 claims 4
- 230000000340 anti-metabolite Effects 0.000 claims 4
- 229940100197 antimetabolite Drugs 0.000 claims 4
- 239000002256 antimetabolite Substances 0.000 claims 4
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims 4
- 229940117893 apigenin Drugs 0.000 claims 4
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims 4
- 235000008714 apigenin Nutrition 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- 229940109262 curcumin Drugs 0.000 claims 4
- 235000012754 curcumin Nutrition 0.000 claims 4
- 239000004148 curcumin Substances 0.000 claims 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 239000002502 liposome Substances 0.000 claims 4
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims 4
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims 4
- 229960003966 nicotinamide Drugs 0.000 claims 4
- 235000005152 nicotinamide Nutrition 0.000 claims 4
- 239000011570 nicotinamide Substances 0.000 claims 4
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 claims 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 4
- 102000020233 phosphotransferase Human genes 0.000 claims 4
- 150000003057 platinum Chemical class 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 230000009467 reduction Effects 0.000 claims 4
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims 4
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims 4
- 230000008313 sensitization Effects 0.000 claims 4
- 239000003734 thymidylate synthase inhibitor Substances 0.000 claims 4
- 230000001988 toxicity Effects 0.000 claims 4
- 231100000419 toxicity Toxicity 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 229920000858 Cyclodextrin Polymers 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 102000001301 EGF receptor Human genes 0.000 claims 3
- 108060006698 EGF receptor Proteins 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 230000008512 biological response Effects 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 201000008274 breast adenocarcinoma Diseases 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 229940127093 camptothecin Drugs 0.000 claims 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 3
- 230000008859 change Effects 0.000 claims 3
- 229960000684 cytarabine Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 3
- 229960005420 etoposide Drugs 0.000 claims 3
- 230000009368 gene silencing by RNA Effects 0.000 claims 3
- 238000001415 gene therapy Methods 0.000 claims 3
- 229940045109 genistein Drugs 0.000 claims 3
- 235000006539 genistein Nutrition 0.000 claims 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 230000010534 mechanism of action Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 229960003539 mitoguazone Drugs 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 239000002777 nucleoside Substances 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 229960003581 pyridoxal Drugs 0.000 claims 3
- 235000008164 pyridoxal Nutrition 0.000 claims 3
- 239000011674 pyridoxal Substances 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 230000008439 repair process Effects 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 229960004964 temozolomide Drugs 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 229930007631 (-)-perillyl alcohol Natural products 0.000 claims 2
- QNOCRUSVMMAKSC-CCEZHUSRSA-N (3e)-1-methyl-3-(2-oxo-1h-indol-3-ylidene)indol-2-one Chemical compound C12=CC=CC=C2N(C)C(=O)\C1=C\1C2=CC=CC=C2NC/1=O QNOCRUSVMMAKSC-CCEZHUSRSA-N 0.000 claims 2
- CLUQWSRYSHBBDD-DYXFYOPSSA-N (4s)-4-[(2-amino-4-methylsulfanylbutanoyl)amino]-5-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-(1h-indol-3-yl)ethyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]- Chemical class C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)C(N)CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 CLUQWSRYSHBBDD-DYXFYOPSSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 2
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 102100031065 Choline kinase alpha Human genes 0.000 claims 2
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 claims 2
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 claims 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims 2
- 229940094664 Cysteine protease inhibitor Drugs 0.000 claims 2
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 2
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 2
- 206010059866 Drug resistance Diseases 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 102000009025 Endorphins Human genes 0.000 claims 2
- 108010049140 Endorphins Proteins 0.000 claims 2
- 229940122601 Esterase inhibitor Drugs 0.000 claims 2
- 108010029961 Filgrastim Proteins 0.000 claims 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 2
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 claims 2
- 101000634975 Homo sapiens Tripartite motif-containing protein 29 Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 2
- 108010038807 Oligopeptides Proteins 0.000 claims 2
- 102000015636 Oligopeptides Human genes 0.000 claims 2
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims 2
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims 2
- 239000012661 PARP inhibitor Substances 0.000 claims 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 108010057464 Prolactin Proteins 0.000 claims 2
- 102000003946 Prolactin Human genes 0.000 claims 2
- 108091008611 Protein Kinase B Proteins 0.000 claims 2
- 108090000315 Protein Kinase C Proteins 0.000 claims 2
- 102000003923 Protein Kinase C Human genes 0.000 claims 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 2
- 239000002262 Schiff base Substances 0.000 claims 2
- 150000004753 Schiff bases Chemical class 0.000 claims 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 2
- 102000005157 Somatostatin Human genes 0.000 claims 2
- 108010056088 Somatostatin Proteins 0.000 claims 2
- 102000011923 Thyrotropin Human genes 0.000 claims 2
- 108010061174 Thyrotropin Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 2
- 108010004977 Vasopressins Proteins 0.000 claims 2
- 102000002852 Vasopressins Human genes 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 2
- 229960003459 allopurinol Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 239000002221 antipyretic Substances 0.000 claims 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 229920002988 biodegradable polymer Polymers 0.000 claims 2
- 239000004621 biodegradable polymer Substances 0.000 claims 2
- 238000001815 biotherapy Methods 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 239000003431 cross linking reagent Substances 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229960002448 dasatinib Drugs 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000003828 downregulation Effects 0.000 claims 2
- 230000012202 endocytosis Effects 0.000 claims 2
- 239000002329 esterase inhibitor Substances 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 229960005102 foscarnet Drugs 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- 229910001385 heavy metal Inorganic materials 0.000 claims 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical group CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 2
- 102000047882 human INSR Human genes 0.000 claims 2
- 238000011577 humanized mouse model Methods 0.000 claims 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- AXESYCSCGBQJBL-SZPBEECKSA-N largazole Chemical compound O=C([C@@]1(C)N=C2SC1)N[C@@H](C(C)C)C(=O)O[C@H](/C=C/CCSC(=O)CCCCCCC)CC(=O)NCC1=NC2=CS1 AXESYCSCGBQJBL-SZPBEECKSA-N 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229960003151 mercaptamine Drugs 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 239000004005 microsphere Substances 0.000 claims 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 2
- 239000002159 nanocrystal Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 229960001346 nilotinib Drugs 0.000 claims 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 235000005693 perillyl alcohol Nutrition 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 229940097325 prolactin Drugs 0.000 claims 2
- 108020001580 protein domains Proteins 0.000 claims 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 2
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 239000003488 releasing hormone Substances 0.000 claims 2
- 239000013557 residual solvent Substances 0.000 claims 2
- 239000011347 resin Substances 0.000 claims 2
- 229920005989 resin Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000037921 secondary disease Diseases 0.000 claims 2
- 239000002002 slurry Substances 0.000 claims 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 2
- 229960000553 somatostatin Drugs 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- 229960003726 vasopressin Drugs 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- 229940045997 vitamin a Drugs 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- BNZPFJBUHRBLNB-UHFFFAOYSA-N 1-oxido-1,2,4-benzotriazin-1-ium Chemical compound C1=CC=C2[N+]([O-])=NC=NC2=C1 BNZPFJBUHRBLNB-UHFFFAOYSA-N 0.000 claims 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 claims 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 claims 1
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 claims 1
- UPALIKSFLSVKIS-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 101150038313 AHI1 gene Proteins 0.000 claims 1
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 claims 1
- 102000006772 Acid Ceramidase Human genes 0.000 claims 1
- 108020005296 Acid Ceramidase Proteins 0.000 claims 1
- 229940123786 Adenosine A3 receptor antagonist Drugs 0.000 claims 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 claims 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 claims 1
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 claims 1
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 claims 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 108091007065 BIRCs Proteins 0.000 claims 1
- 101000796998 Bacillus subtilis (strain 168) Methylated-DNA-protein-cysteine methyltransferase, inducible Proteins 0.000 claims 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 1
- 108091007914 CDKs Proteins 0.000 claims 1
- 229940043709 CaM kinase II inhibitor Drugs 0.000 claims 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 102000052052 Casein Kinase II Human genes 0.000 claims 1
- 108010010919 Casein Kinase II Proteins 0.000 claims 1
- 108010018888 Choline kinase Proteins 0.000 claims 1
- 101710095468 Cyclase Proteins 0.000 claims 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 239000012625 DNA intercalator Substances 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 claims 1
- 101100181139 Drosophila melanogaster Pkcdelta gene Proteins 0.000 claims 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 1
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102000005720 Glutathione transferase Human genes 0.000 claims 1
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 1
- 229940122588 Heparanase inhibitor Drugs 0.000 claims 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims 1
- 101710184069 Hepatocyte growth factor receptor Proteins 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims 1
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 claims 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 102000042838 JAK family Human genes 0.000 claims 1
- 108091082332 JAK family Proteins 0.000 claims 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 101150021395 JUND gene Proteins 0.000 claims 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 229940113306 Ligase inhibitor Drugs 0.000 claims 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 claims 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 claims 1
- 229940083338 MDM2 inhibitor Drugs 0.000 claims 1
- 239000012819 MDM2-Inhibitor Substances 0.000 claims 1
- 229940124761 MMP inhibitor Drugs 0.000 claims 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims 1
- 102000002151 Microfilament Proteins Human genes 0.000 claims 1
- 108010040897 Microfilament Proteins Proteins 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 claims 1
- 108091022875 Microtubule Proteins 0.000 claims 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 claims 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 1
- 101150056950 Ntrk2 gene Proteins 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 108010049358 Oncogene Protein p65(gag-jun) Proteins 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 108020005115 Pyruvate Kinase Proteins 0.000 claims 1
- 102000013009 Pyruvate Kinase Human genes 0.000 claims 1
- 102000014128 RANK Ligand Human genes 0.000 claims 1
- 108010025832 RANK Ligand Proteins 0.000 claims 1
- 102000009572 RNA Polymerase II Human genes 0.000 claims 1
- 108010009460 RNA Polymerase II Proteins 0.000 claims 1
- 229940123690 Raf kinase inhibitor Drugs 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 229940123934 Reductase inhibitor Drugs 0.000 claims 1
- 108010083644 Ribonucleases Proteins 0.000 claims 1
- 102000006382 Ribonucleases Human genes 0.000 claims 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims 1
- 101150099493 STAT3 gene Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102100020824 Serine-protein kinase ATM Human genes 0.000 claims 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims 1
- 241000710960 Sindbis virus Species 0.000 claims 1
- 229940121856 Somatostatin receptor antagonist Drugs 0.000 claims 1
- 229940122171 Sphingomyelinase inhibitor Drugs 0.000 claims 1
- 229940122924 Src inhibitor Drugs 0.000 claims 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 108010017842 Telomerase Proteins 0.000 claims 1
- 229940123582 Telomerase inhibitor Drugs 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 claims 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 102100023132 Transcription factor Jun Human genes 0.000 claims 1
- 102100029519 Tripartite motif-containing protein 29 Human genes 0.000 claims 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims 1
- 102000014384 Type C Phospholipases Human genes 0.000 claims 1
- 108010079194 Type C Phospholipases Proteins 0.000 claims 1
- 229940076850 Tyrosine phosphatase inhibitor Drugs 0.000 claims 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 1
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 claims 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 1
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010092464 Urate Oxidase Proteins 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 1
- 229940123429 VEGFR tyrosine kinase inhibitor Drugs 0.000 claims 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims 1
- 239000012345 acetylating agent Substances 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002580 adenosine A3 receptor antagonist Substances 0.000 claims 1
- 239000003121 adenosine kinase inhibitor Substances 0.000 claims 1
- 230000001780 adrenocortical effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229960004701 amonafide Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000001142 anti-diarrhea Effects 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000003457 anti-vomiting effect Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 239000000158 apoptosis inhibitor Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000003190 augmentative effect Effects 0.000 claims 1
- 239000005441 aurora Substances 0.000 claims 1
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 238000002725 brachytherapy Methods 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 108010046616 cdc25 Phosphatases Proteins 0.000 claims 1
- 102000007588 cdc25 Phosphatases Human genes 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 claims 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims 1
- 229960001380 cimetidine Drugs 0.000 claims 1
- 230000003081 coactivator Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 150000001944 cysteine derivatives Chemical class 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 102000004419 dihydrofolate reductase Human genes 0.000 claims 1
- 239000012990 dithiocarbamate Substances 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000001973 epigenetic effect Effects 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 229960004177 filgrastim Drugs 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
- 229960001442 gonadorelin Drugs 0.000 claims 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 1
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 108010039490 largazole Proteins 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 239000000436 ligase inhibitor Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 150000002678 macrocyclic compounds Chemical class 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims 1
- 210000004688 microtubule Anatomy 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 229940029345 neupogen Drugs 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 230000005937 nuclear translocation Effects 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 claims 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 230000003285 pharmacodynamic effect Effects 0.000 claims 1
- 238000011458 pharmacological treatment Methods 0.000 claims 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 1
- 229960003243 phenformin Drugs 0.000 claims 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 claims 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 claims 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 claims 1
- 150000008299 phosphorodiamidates Chemical class 0.000 claims 1
- 239000003504 photosensitizing agent Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 229920000768 polyamine Polymers 0.000 claims 1
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 108700042226 ras Genes Proteins 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 1
- 239000003590 rho kinase inhibitor Substances 0.000 claims 1
- 238000009118 salvage therapy Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 108091006024 signal transducing proteins Proteins 0.000 claims 1
- 102000034285 signal transducing proteins Human genes 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000002732 sphingomyelin phosphodiesterase inhibitor Substances 0.000 claims 1
- 229950006315 spirogermanium Drugs 0.000 claims 1
- 108010087686 src-Family Kinases Proteins 0.000 claims 1
- 102000009076 src-Family Kinases Human genes 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 1
- 231100000617 superantigen Toxicity 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 1
- 239000003277 telomerase inhibitor Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000009452 underexpressoin Effects 0.000 claims 1
- 229940116269 uric acid Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829739P | 2013-05-31 | 2013-05-31 | |
| US61/829,739 | 2013-05-31 | ||
| PCT/US2014/040461 WO2014194312A2 (en) | 2013-05-31 | 2014-06-02 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020013217A Division JP2020079259A (ja) | 2013-05-31 | 2020-01-30 | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520622A JP2016520622A (ja) | 2016-07-14 |
| JP2016520622A5 true JP2016520622A5 (enExample) | 2017-07-13 |
Family
ID=51989551
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517073A Pending JP2016520622A (ja) | 2013-05-31 | 2014-06-02 | 再発性悪性神経膠腫又は進行性の二次性脳腫瘍を治療するためのジアンヒドロガラクチトール並びにその類似体及び誘導体の使用 |
| JP2020013217A Pending JP2020079259A (ja) | 2013-05-31 | 2020-01-30 | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 |
| JP2022062257A Pending JP2022088616A (ja) | 2013-05-31 | 2022-04-04 | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020013217A Pending JP2020079259A (ja) | 2013-05-31 | 2020-01-30 | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 |
| JP2022062257A Pending JP2022088616A (ja) | 2013-05-31 | 2022-04-04 | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11026914B2 (enExample) |
| EP (1) | EP3003321A4 (enExample) |
| JP (3) | JP2016520622A (enExample) |
| KR (4) | KR20210100754A (enExample) |
| CN (1) | CN105579044A (enExample) |
| AU (2) | AU2014273911B2 (enExample) |
| BR (1) | BR112015029989A2 (enExample) |
| CA (1) | CA2914025C (enExample) |
| CL (1) | CL2015003512A1 (enExample) |
| IL (1) | IL242853B (enExample) |
| MX (1) | MX382824B (enExample) |
| SG (1) | SG11201509837QA (enExample) |
| TW (1) | TW201536278A (enExample) |
| WO (1) | WO2014194312A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014179528A2 (en) * | 2013-05-01 | 2014-11-06 | Brown Dennis M | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| WO2016138542A1 (en) * | 2015-02-28 | 2016-09-01 | Cyprus Therapeutics, Inc. | Methods for inhibiting tumors and drug resistance |
| TW201722421A (zh) * | 2015-09-10 | 2017-07-01 | 德瑪製藥公司 | 雙脫水半乳糖醇或其衍生物和類似物藉由ｄｎａ損傷之誘導和細胞周期之延宕治療非小細胞肺癌、神經膠母細胞瘤及卵巢癌之用途 |
| AU2016382786A1 (en) * | 2015-12-29 | 2018-07-19 | Outlook Therapeutics, Inc. | Buffered formulations of bevacizumab |
| WO2018204323A1 (en) * | 2017-05-01 | 2018-11-08 | Del Mar Pharmaceuticals (Bc) Ltd. | Use of dianhydrogalactitol or analogs and derivatives in combination with vegf inhibitors to treat cancer |
| US10624869B2 (en) | 2017-05-08 | 2020-04-21 | Stanislaw R. Burzynski | Methods for the treatment of recurrent glioblastoma (RGBM) |
| WO2018226939A1 (en) * | 2017-06-07 | 2018-12-13 | Ranedis Pharmaceuticals, Llc | Compositions and methods of treating and/or preventing cancer |
| US11344521B2 (en) | 2017-06-12 | 2022-05-31 | Burzynski Research Institute, Inc. | Methods for the treatment of leptomeningeal disease |
| KR20230124107A (ko) * | 2017-06-12 | 2023-08-24 | 스탠니슬로우 알 벌진스키 | 연수막 질환의 치료 방법 |
| KR20200052349A (ko) | 2017-09-11 | 2020-05-14 | 아토사 테라퓨틱스, 인크. | 엔독시펜을 제조 및 사용하는 방법 |
| WO2019211708A1 (en) * | 2018-05-04 | 2019-11-07 | Kashiv Biosciences, Llc | Stable pharmaceutical compositions of dianhydrogalactitol |
| CN109337884B9 (zh) * | 2018-12-21 | 2021-10-29 | 中国农业科学院北京畜牧兽医研究所 | 一种丙酮酸激酶基因及其应用 |
| US12201591B2 (en) | 2019-07-03 | 2025-01-21 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
| KR102415193B1 (ko) | 2020-04-16 | 2022-06-29 | 사회복지법인 삼성생명공익재단 | 벤즈브로마론을 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학 조성물 |
| WO2021252432A1 (en) * | 2020-06-08 | 2021-12-16 | Neonc Technologies, Inc. | Compositions and methods for delivering polynucleotides |
| CN114796522A (zh) * | 2022-01-06 | 2022-07-29 | 宁波大学 | 一种靶向线粒体放大氧化应激的新型抗肿瘤纳米药物 |
| WO2024039764A2 (en) * | 2022-08-17 | 2024-02-22 | Ohio State Innovation Foundation | Epitranscriptomic analysis of glioma |
| KR20250052523A (ko) | 2023-10-11 | 2025-04-21 | 서울대학교병원 | 재발성 뇌 종양 진단, 예방 또는 치료에서의 cxcr-4의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4785077A (en) | 1986-05-05 | 1988-11-15 | Scripps Clinic And Research Foundation | Substantially pure cytotoxicity triggering factor |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5294430A (en) * | 1988-09-12 | 1994-03-15 | University Of Rochester | Use of dithiocarbamates to treat myelosuppression |
| EP2605650A4 (en) * | 2010-08-18 | 2014-05-21 | Del Mar Pharmaceuticals | COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYL DIANHYDROGALACTITOL |
| CN110711188A (zh) | 2012-01-20 | 2020-01-21 | 德玛公司 | 经取代的己糖醇类用于治疗恶性肿瘤的用途 |
| US9814693B2 (en) * | 2012-05-09 | 2017-11-14 | Delmar Pharmaceuticals, Inc. | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
-
2014
- 2014-05-30 TW TW103118945A patent/TW201536278A/zh unknown
- 2014-06-02 MX MX2015016404A patent/MX382824B/es unknown
- 2014-06-02 WO PCT/US2014/040461 patent/WO2014194312A2/en not_active Ceased
- 2014-06-02 AU AU2014273911A patent/AU2014273911B2/en not_active Ceased
- 2014-06-02 BR BR112015029989A patent/BR112015029989A2/pt not_active Application Discontinuation
- 2014-06-02 KR KR1020217025060A patent/KR20210100754A/ko not_active Ceased
- 2014-06-02 JP JP2016517073A patent/JP2016520622A/ja active Pending
- 2014-06-02 CN CN201480042784.2A patent/CN105579044A/zh active Pending
- 2014-06-02 EP EP14804823.4A patent/EP3003321A4/en not_active Withdrawn
- 2014-06-02 KR KR1020227018071A patent/KR20220080199A/ko not_active Ceased
- 2014-06-02 SG SG11201509837QA patent/SG11201509837QA/en unknown
- 2014-06-02 KR KR1020237027741A patent/KR20230124765A/ko not_active Ceased
- 2014-06-02 KR KR1020157037286A patent/KR20160065776A/ko not_active Ceased
- 2014-06-02 CA CA2914025A patent/CA2914025C/en active Active
-
2015
- 2015-04-09 US US14/682,226 patent/US11026914B2/en active Active
- 2015-11-30 IL IL242853A patent/IL242853B/en unknown
- 2015-11-30 CL CL2015003512A patent/CL2015003512A1/es unknown
-
2019
- 2019-12-18 AU AU2019283893A patent/AU2019283893B2/en not_active Ceased
-
2020
- 2020-01-30 JP JP2020013217A patent/JP2020079259A/ja active Pending
-
2022
- 2022-04-04 JP JP2022062257A patent/JP2022088616A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520622A5 (enExample) | ||
| US12336993B2 (en) | Therapeutic benefit of suboptimally administered chemical compounds | |
| JP2022088616A (ja) | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 | |
| JP2016519684A5 (enExample) | ||
| JP2021004244A (ja) | 多形神経膠芽腫及び髄芽腫を含む新生物疾患及び癌幹細胞を処置するためのジアンヒドロガラクチトール及び類似体を含めた置換ヘキシトールの使用 | |
| US20180221395A1 (en) | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | |
| JP2013537552A5 (ja) | ジアンヒドロガラクチトール及びジアセチルジアンヒドロガラクチトール等の置換ヘキシトールを含む準最適に投与された化合物の治療的有効性を改良するための組成物及び置換ヘキシトールを含む薬剤を調製するための方法 | |
| JP2017512841A5 (enExample) | ||
| JP2015526410A5 (enExample) | ||
| US20160271133A1 (en) | Methods of Treating Multiple Myeloma and Resistant Cancers | |
| KR20170017932A (ko) | Ｍｄｍ２ 억제제의 간헐적 투여 | |
| US9370535B2 (en) | Method for treatment of advanced solid tumors | |
| US20160303131A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies | |
| Facchetti et al. | Malignant Pleural Mesothelioma: State of the art and advanced cell therapy | |
| JP2015514796A (ja) | ２から３０ｍｇ／ｋｇの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体 | |
| AU2008206575B2 (en) | Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives | |
| JP2021522345A (ja) | 新規なｍｃｔ４阻害剤及びその使用 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| US20230038138A1 (en) | Combination therapy for treating cancer | |
| JP5590560B2 (ja) | 組合せ抗がん剤 | |
| KR20160038895A (ko) | 암 화학 요법시의 부작용 경감제 | |
| NL2020004B1 (en) | Treatment of diffuse intrinsic pontine glioma | |
| WO2024023766A1 (en) | P13k inhibitor combination therapy | |
| WO2021053523A1 (en) | Compositions and methods to improve the therapeutic benefit of bis-dioxopiperazines | |
| CN117357528A (zh) | 一种激酶抑制剂的新用途 |